01041nas a2200397   4500000000100000000000100001000000100002008004100003653001000044653001100054653002700065653001500092653003300107653001400140653001900154653003100173653002800204653002400232653003200256653001300288653001700301653004200318100001200360700001900372700001400391700001200405700001300417700001500430700002300445700001400468245011700482250001500599300000800614490000700622020001400629       2023                            d10aAdult10aHumans10a*COVID-19/epidemiology10aSARS-CoV-210aPost-Acute COVID-19 Syndrome10aIncidence10aCohort Studies10a*Diabetes Mellitus, Type 110aImmunomodulating Agents10aPrimary health care10aUnited Kingdom/epidemiology10aCovid-1910aCohort study10aImmune-mediated inflammatory diseases1 aU. Syed1 aA. Subramanian1 aD. Wraith1 aJ. Lord1 aK. McGee1 aK. Ghokale1 aK. Nirantharakumar1 aS. Haroon00aIncidence of immune-mediated inflammatory diseases following COVID-19: a matched cohort study in UK primary care  a2023/09/22  a3630 v21  a1741-7015